文献速递妇科

长效醋酸甲羟孕酮使用与子宫平滑肌瘤发生及进展的关系

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma.
PubMed 文献 · Obstet Gynecol · 2022-04-05

在底特律地区开展队列研究,2010至2018年对1693名23-35岁自我认同为黑人的无肌瘤女性每20个月随访一次,用标准化超声前瞻性测量直径≥0.5cm的肌瘤。分析显示,近2年内使用长效醋酸甲羟孕酮者相比从未使用者肌瘤发生率更低(5.2% vs 10.7%),调整风险比0.6(95%CI 0.4-1.0),肌瘤生长减少42.0%,肌瘤消退增加60%。

要点

  • 近2年内使用DMPA者肌瘤发生率5.2%,从未使用者10.7%,调整HR 0.6(95%CI 0.4-1.0)。
  • 近2年内使用DMPA者肌瘤生长减少42.0%(95%CI -51.4至-30.7),肌瘤消退增加60%(调整RR 1.6,95%CI 1.1-2.2)。
  • 2-4年前使用DMPA者相比从未使用者肌瘤消退增加2.1倍(95%CI 1.4-3.1)。

核心结论

  • 近期使用DMPA与肌瘤发生减少和肌瘤消退增加相关。
  • 年轻女性早期肌瘤发生的这种变化可能延迟症状出现并减少侵入性治疗的需求。

研究设计与样本

  • 在密歇根州底特律地区开展的队列研究,2010至2018年共5年,每20个月一次诊所访视,共四次。
  • 采用标准化超声方案前瞻性测量直径≥0.5cm的肌瘤。
  • 参与者为1693名自我认同为黑人的女性,年龄23-35岁,既往无肌瘤诊断且未行子宫切除术。
  • 至少有一次随访的参与者共1610名,其中42.9%曾使用过DMPA。
  • 采用Cox模型分析DMPA与肌瘤发生的关联,线性混合模型分析肌瘤生长,泊松回归分析肌瘤消退,所有模型均使用时变暴露和协变量。

主要发现

  • 近2年内使用DMPA者相比从未使用者肌瘤发生率更低(5.2% vs 10.7%),调整风险比0.6(95%CI 0.4-1.0)。
  • 近2年内使用DMPA者相比从未使用者肌瘤生长减少42.0%(95%CI -51.4至-30.7)。
  • 近2年内使用DMPA者相比从未使用者肌瘤消退增加60%(调整风险比1.6,95%CI 1.1-2.2)。
  • 2-4年前使用DMPA者相比从未使用者肌瘤消退增加2.1倍(95%CI 1.4-3.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate the association between use of depot medroxyprogesterone acetate (DMPA) (an injectable progestin-only contraceptive) and leiomyoma development. METHODS: We conducted a cohort study in the Detroit, Michigan, area that involved four clinic visits at 20-month intervals over 5 years (2010-2018) and used a standardized ultrasonography protocol to prospectively measure leiomyomas 0.5 cm or more in diameter. Participants were 1,693 self-identified Black women aged 23-35 years with no prior leiomyoma diagnosis and no hysterectomy. For this substudy, years since last use of DMPA was ascertained from questionnaire data at every visit. Leiomyoma incidence was defined as the first visit with an observed leiomyoma among women who were leiomyoma-free at enrollment. Depot medroxyprogesterone acetate associations were examined with Cox models. Leiomyoma growth was calculated as the change in log-volume for leiomyomas matched at successive visits and was modeled using linear mixed models accounting for clustered data. Leiomyoma loss, defined as a reduction in leiomyoma number in successive visits, was modeled using Poisson regression. All models used time-varying exposure and covariates. RESULTS: Of participants with at least one follow-up visit (N=1,610), 42.9% had ever used DMPA. Participants exposed to DMPA within the previous 2 years experienced reduced leiomyoma development during the subsequent observation interval compared with never users, including lower leiomyoma incidence (5.2% vs 10.7%), adjusted hazard ratio 0.6 (95% CI 0.4-1.0), 42.0% lower leiomyoma growth (95% CI -51.4 to -30.7) and 60% greater leiomyoma loss (adjusted risk ratio 1.6, 95% CI 1.1-2.2). Excess leiomyoma loss was also seen for those who used DMPA 2-4 years before the visit compared with never users, 2.1-fold increase (95% CI 1.4-3.1). CONCLUSION: Recent use of DMPA was associated with reduced leiomyoma development and increased leiomyoma loss. Such changes in early leiomyoma development in young women could delay symptom onset and reduce the need for invasive treatment.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Harmon QE, Patchel SA, Zhao S, et al. Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma. Obstet Gynecol. 2022. PMID: 35576339. doi:10.1097/AOG.0000000000004745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。